
Breaking News: InflaRx Receives Positive CHMP Opinion for Vilobelimab, a Promising Treatment for SARS-CoV-2 Induced Acute Respiratory Distress Syndrome
Innovative Treatment for SARS-CoV-2-induced ARDS Exciting news has come out of Jena, Germany, as InflaRx N.V. announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization of GOHIBIC (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). This breakthrough therapy targets the complement…